DB15472ExperimentalProtein Based Therapies
According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload." It is being...
- Mechanism
- Curator reviewed
Pharmacologically active on Epidermal growth factor receptor
- Also known as
- anti-HER2 x HER2 ADC
- Code names
- ZW-49
Resolves to
Compound
Targets
What you can answer from here — as of October 17, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Zanidatamab zovodotin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account